Bioactor and Ferrer HealthTech sign Collaboration Agreement
date:Jan 22, 2014
noside formulation for cardiovascular health, has shown strong clinical data on the improvement of endothelial function. Parties have completed a pharmacokinetics study showing the high bioavailability of cordiart.

Bioactorand Ferrer HealthTechare co-financing a robust research programme on additional health effects of certain citric flavonoids in the course of which at least 3 additional clinical studies will be performed. Hans van der Saag, Managing Director ofBioactorcomments; our joint clin
2/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/26 14:56